You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


BMS opts-in on Evotec’s neurodegenerative medicine

Bristol Myers Squibb (BMS) has opted-in to an exclusive global license for Evotec’s neurodegenerative drug EVT8683.